Immunocore Holdings plc reports commercial and clinical developments for a biotechnology issuer whose Nasdaq-listed ADSs represent ordinary shares. The company uses its ImmTAX TCR bispecific immunotherapy platform across oncology, infectious disease and autoimmune programs, with KIMMTRAK (tebentafusp-tebn) approved for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia and the United Kingdom.
Recurring updates cover KIMMTRAK sales and long-term survival data, lifecycle-management studies in uveal and cutaneous melanoma, the PRAME-A02 candidate brenetafusp, earlier ImmTAX candidates, HIV functional-cure research, autoimmune disease pipeline activity, financial results, investor presentations and R&D governance changes.
Immunocore (NASDAQ:IMCR) reported strong Q2 2025 financial results, with KIMMTRAK net revenues reaching $98.0 million, representing a 30% year-over-year growth. The company achieved significant market expansion with KIMMTRAK now approved in 39 countries and launched in 28 countries globally.
Key highlights include 15% growth in US sales and 71% growth in Europe and international regions. The company maintains a strong financial position with $883 million in cash and equivalents. R&D expenses increased to $69.0 million, reflecting investments in autoimmune programs and Phase 3 trials.
Clinical progress remains on track with the Phase 3 TEBE-AM trial expected to complete enrollment in 1H 2026, and dose selection for PRISM-MEL-301 Phase 3 trial anticipated in 2H 2025. The company reported a reduced net loss of $10.3 million compared to $11.6 million in the same period last year.
Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company, will release its second quarter 2025 financial results on Thursday, August 7, 2025, before US markets open. The company will host a conference call and webcast at 8:00 a.m. EDT to discuss results and provide business updates.
Immunocore specializes in developing novel TCR bispecific immunotherapies (ImmTAX) for cancer, autoimmune, and infectious diseases. Their lead product, KIMMTRAK, is approved in multiple regions for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
AeroVironment (NASDAQ: AVAV) has scheduled its third quarter fiscal year 2025 financial results announcement for Tuesday, March 4, 2025, after market close. The company will host a conference call and live audio webcast at 4:30 p.m. Eastern Time on the same day.
The earnings call will feature presentations from key executives including Wahid Nawabi (Chairman, President, and CEO), Kevin P. McDonnell (Senior VP and CFO), and Jonah Teeter-Balin (VP of Corporate Development and Investor Relations).
Investors can participate by registering through the provided link up to 10 minutes before the event. The webcast will be accessible through AeroVironment's Investor Relations website, with an audio replay available shortly after the event.
Immunocore (NASDAQ: IMCR) has presented initial data from the multiple ascending dose (MAD) portion of its Phase 1/2 STRIVE trial for IMC-M113V, a functional HIV cure candidate. The study included 16 HIV-positive participants across three dose cohorts (60 mcg, 120 mcg, and 300 mcg).
Key findings show that IMC-M113V was well-tolerated with no serious adverse events. The 300 mcg cohort showed promising results, with 2 out of 5 patients demonstrating viral control. Notably, these patients maintained viral loads around 200 c/mL at week 8, significantly better than the historical rate of 5%.
The trial revealed dose-dependent viral control after antiretroviral treatment interruption, with some patients showing reduced CD4+ T cell-associated HIV Gag RNA, indicating a reduction in active virus reservoir. Two patients remained off antiretroviral treatment for the entire 12-week interruption period, with one patient showing viral reduction to 50 c/mL at week 12 - an outcome typically seen in <1% of cases.
Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, has announced its participation in three major investor conferences in March 2025.
The company will be present at:
- The TD Cowen 45th Annual Healthcare Conference with a presentation on Tuesday, March 4, 2025, at 3:10 p.m. EST
- The Barclays 27th Annual Global Healthcare Conference for a fireside chat on Tuesday, March 11, 2025, at 3:00 p.m. EST
- The Jefferies Biotech on the Beach Summit for one-on-one and small group meetings on Wednesday, March 12, 2025
Interested parties can access live webcasts of the presentations through the 'Events & Presentations' section under 'Events' in the 'Investors' area of Immunocore's website. Replay options will be available for a time after the events.
Immunocore (NASDAQ: IMCR) reported Q4 2024 financial results with KIMMTRAK net sales of $84.1M and full-year sales of $310.0M. The company achieved 11 consecutive quarters of revenue growth and expanded to 14 new territories.
Q4 net loss was $23.8M ($0.47 per share) compared to $19.7M in Q4 2023. Full-year 2024 net loss was $51.1M ($1.02 per share) versus $55.3M in 2023. R&D expenses increased to $222.2M from $163.5M in 2023.
Key developments include:
- KIMMTRAK now approved in 39 countries and launched in 24
- First patient randomized in Phase 3 PRISM-MEL-301 trial
- Initiated Phase 1/2 trial of IMC-R117C for colorectal cancers
- Strong cash position of $820.4M as of December 31, 2024
- Repaid $50M Pharmakon loan in November 2024
Immunocore Holdings (Nasdaq: IMCR), a commercial-stage biotechnology company focused on immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, has announced it will release its fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025.
The company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss the financial results and provide updates on its business and portfolio. The webcast will be accessible through the 'Events' section of Immunocore's website, with a replay available for a time afterward.
Immunocore Holdings (Nasdaq: IMCR) outlined its strategic priorities for 2025, focusing on expanding KIMMTRAK's global reach and advancing its clinical portfolio. The company is currently enrolling three Phase 3 trials across multiple melanoma indications, with initial data readouts expected in 2026.
Key priorities include building a melanoma franchise through additional launches and increased community penetration, with KIMMTRAK now available in 23 countries. The company is advancing multiple clinical trials, including Phase 1/2 trials with brenetafusp combinations in ovarian and lung cancer, and ongoing dose escalation studies.
The company plans to submit clinical trial applications for two autoimmune disease candidates: IMC-S118AI for Type 1 diabetes in 2025 and IMC-U120AI for atopic dermatitis in 2026. Preliminary unaudited cash position was approximately $820 million as of December 31, 2024.